Join to view full profile
1951 E 120th StApt 2Seattle, WA 44106
Phone+1 206-744-3241
Dr. Frohlich is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 1990 - 1994
Harvard Medical SchoolClass of 1990
Certifications & Licensure
WA State Medical License 2002 - 2026
Clinical Trials
Publications & Presentations
PubMed
- 106 citationsHumoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical OutcomeDebraj GuhaThakurta, Nadeem A. Sheikh, Li-Qun Fan, Harini Kandadi, T. Craig Meagher
Clinical Cancer Research. 2015-08-15 - 240 citationsActivated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate CancerLawrence Fong, Peter R. Carroll, Vivian Weinberg, Stephen Chan, Jera Lewis
Journal of the National Cancer Institute. 2014-11-01 - 22 citationsTime to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-TEric J. Small, Celestia S. Higano, Philip W. Kantoff, James Boyd Whitmore, Mark W. Frohlich
Prostate Cancer and Prostatic Diseases. 2014-06-24
Press Mentions
Register NowJuly 19th, 2024
NEUVOGEN Appoints Dr. Mark W. Frohlich, a World-Renowned Immunotherapy Expert to Its Board of Directors and Scientific Advisory BoardAugust 23rd, 2021
Survey: Hoosier Manufacturers Expect to Weather COVID StormNovember 19th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
